Literature DB >> 14755031

The potential epidemiological impact of a genital herpes vaccine for women.

G P Garnett1, G Dubin, M Slaoui, T Darcis.   

Abstract

BACKGROUND: In two phase III vaccine trials immunisation of women previously uninfected by herpes simplex virus provided protection against genital herpes disease. In deciding policy, an evaluation of the epidemiological impact of the partial protection provided by the vaccine should be considered.
METHODS: A sex and sexual activity stratified deterministic differential and partial differential equation model of the natural history of herpes simplex virus type 2 (HSV-2) and the impact of vaccination is developed and analysed. To explore the role of vaccination, the pattern of viral shedding and the transmission of infection during sexual acts within sexual partnerships are described.
RESULTS: Using literature derived estimates of parameter values and assuming efficacy in only 40% of women the impact of the vaccine depends on assumptions made about its action. The vaccine has a limited impact if it only prevents disease but a more substantial impact if it reduces asymptomatic viral shedding, which it could do indirectly by preventing infection or directly by modifying the biology of the infection. Concern over the implications of a vaccine that prevents disease but has no impact on viral shedding was addressed in a worst case scenario. Here there is a modest increase in the incidence of infection in both men and women but an increase in disease prevalence in men alone, since the virus directly protects some women from disease.
CONCLUSIONS: Results suggest that a herpes vaccine should be used universally and that a vaccine that only protects HSV-1-/2- women can paradoxically have a significant epidemiological impact, the scale of which depends upon changes in patterns of viral shedding.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14755031      PMCID: PMC1758372          DOI: 10.1136/sti.2002.003848

Source DB:  PubMed          Journal:  Sex Transm Infect        ISSN: 1368-4973            Impact factor:   3.519


  16 in total

1.  Mathematical models of the transmission and control of sexually transmitted diseases.

Authors:  R M Anderson; G P Garnett
Journal:  Sex Transm Dis       Date:  2000-11       Impact factor: 2.830

2.  Measuring the risk of HIV transmission.

Authors:  G P Garnett; J A Røttingen
Journal:  AIDS       Date:  2001-03-30       Impact factor: 4.177

3.  Estimability and interpretation of vaccine efficacy using frailty mixing models.

Authors:  M E Halloran; I M Longini; C J Struchiner
Journal:  Am J Epidemiol       Date:  1996-07-01       Impact factor: 4.897

4.  A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group.

Authors:  A G Langenberg; L Corey; R L Ashley; W P Leong; S E Straus
Journal:  N Engl J Med       Date:  1999-11-04       Impact factor: 91.245

5.  Sex acts, sex partners, and sex budgets: implications for risk factor analysis and estimation of HIV transmission probabilities.

Authors:  S M Blower; C Boe
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1993-12

6.  Use of antiviral treatment and prophylaxis is unlikely to have a major impact on the prevalence of herpes simplex virus type 2.

Authors:  P J White; G P Garnett
Journal:  Sex Transm Infect       Date:  1999-02       Impact factor: 3.519

7.  Frequency of acquisition of first-episode genital infection with herpes simplex virus from symptomatic and asymptomatic source contacts.

Authors:  G J Mertz; O Schmidt; J L Jourden; M E Guinan; M L Remington; A Fahnlander; C Winter; K K Holmes; L Corey
Journal:  Sex Transm Dis       Date:  1985 Jan-Mar       Impact factor: 2.830

8.  Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment.

Authors:  A Wald; L Corey; R Cone; A Hobson; G Davis; J Zeh
Journal:  J Clin Invest       Date:  1997-03-01       Impact factor: 14.808

9.  Glycoprotein-D-adjuvant vaccine to prevent genital herpes.

Authors:  Lawrence R Stanberry; Spotswood L Spruance; Anthony L Cunningham; David I Bernstein; Adrian Mindel; Stephen Sacks; Stephen Tyring; Fred Y Aoki; Moncef Slaoui; Martine Denis; Pierre Vandepapeliere; Gary Dubin
Journal:  N Engl J Med       Date:  2002-11-21       Impact factor: 91.245

10.  Risk factors for the sexual transmission of genital herpes.

Authors:  G J Mertz; J Benedetti; R Ashley; S A Selke; L Corey
Journal:  Ann Intern Med       Date:  1992-02-01       Impact factor: 25.391

View more
  15 in total

1.  Current status and prospects for development of an HSV vaccine.

Authors:  Christine Johnston; David M Koelle; Anna Wald
Journal:  Vaccine       Date:  2013-09-06       Impact factor: 3.641

Review 2.  HSV-2: in pursuit of a vaccine.

Authors:  Christine Johnston; David M Koelle; Anna Wald
Journal:  J Clin Invest       Date:  2011-12-01       Impact factor: 14.808

3.  Estradiol improves genital herpes vaccine efficacy in mice.

Authors:  Jeffry W Pennock; Rachael Stegall; Brent Bell; Gracie Vargas; Massoud Motamedi; Gregg Milligan; Nigel Bourne
Journal:  Vaccine       Date:  2009-08-04       Impact factor: 3.641

4.  Quantification of poly(I:C)-mediated protection against genital herpes simplex virus type 2 infection.

Authors:  Melissa M Herbst-Kralovetz; Richard B Pyles
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

5.  A Vaxfectin(®)-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes.

Authors:  Ronald L Veselenak; Mark Shlapobersky; Richard B Pyles; Qun Wei; Sean M Sullivan; Nigel Bourne
Journal:  Vaccine       Date:  2012-10-04       Impact factor: 3.641

6.  Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs.

Authors:  Yo Hoshino; Lesley Pesnicak; Kennichi C Dowdell; Peter D Burbelo; David M Knipe; Stephen E Straus; Jeffrey I Cohen
Journal:  J Infect Dis       Date:  2009-10-01       Impact factor: 5.226

Review 7.  Varicella zoster vaccines and their implications for development of HSV vaccines.

Authors:  Anne A Gershon
Journal:  Virology       Date:  2013-01-05       Impact factor: 3.616

8.  Population-level effect of potential HSV2 prophylactic vaccines on HIV incidence in sub-Saharan Africa.

Authors:  Esther E Freeman; Richard G White; Roel Bakker; Kate K Orroth; Helen A Weiss; Anne Buvé; Richard J Hayes; Judith R Glynn
Journal:  Vaccine       Date:  2008-12-09       Impact factor: 3.641

9.  An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection.

Authors:  Katharine J Looker; Geoffrey P Garnett; George P Schmid
Journal:  Bull World Health Organ       Date:  2008-10       Impact factor: 9.408

10.  Epidemiological impact of a genital herpes type 2 vaccine for young females.

Authors:  Yijun Lou; Redouane Qesmi; Qian Wang; Marc Steben; Jianhong Wu; Jane M Heffernan
Journal:  PLoS One       Date:  2012-10-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.